CVS Health beat analyst estimates on its fourth-quarter profits and revenues with a lift from gains in product sales and front-store comps.
Company net income was $2.94 billion, or $2.30 per diluted share, versus $1.64 billion, or $1.30 per diluted share, in the year-prior quarter. Adjusted for one-time events, company net income was $1.39 billion, or $1.09 per diluted share, versus $1.51 billion, or $1.19 per diluted share, in the year-earlier period.
A Zacks Investment Research analyst consensus estimate pegged CVS earnings per adjusted diluted share at 99 cents and revenues at $103.44 billion.
Total revenues were $105.69 billion versus $97.71 billion in the year-previous quarter, while product sales came in at $67.04 billion versus $61.91 billion, the company reported. Operating income was $2.11 billion versus $2.37 billion in the year-before period, while adjusted operating income was $2.6 billion versus $2.73 billion.
In the Pharmacy & Consumer Wellness segment, total revenues were $37.66 billion, while adjusted operating income was $1.91 billion versus $33.51 billion and $1.76 billion, respectively, in the year-past period. Front store comparable sales, including general merchandise, increased 0.5% year over year, while overall comps advanced 16%.
Full-year company net income was $1.77 billion, or $1.39 per diluted share, versus $4.61 billion, or $3.66 per diluted share in the year prior. Adjusted company net income was $8.57 billion, or $6.75 per diluted share, versus $6.84 billion, or $5.42 per diluted share in the year earlier.
For the full year, total revenues were $402.07 billion versus $372.81 billion in the year previous, while product sales came in at $249.91 billion versus $231.52 billion, CVS stated. Operating income was $4.66 billion versus $8.52 billion in the year before, while adjusted operating income was $14.44 billion versus $11.98 billion.
CVS affirmed its previous full year 2026 guidance of diluted earnings per share in a range of $5.94 to $6.14 and adjusted EPS in a range of $7 to $7.20.
In announcing the financial results, David Joyner, CVS Health president and CEO, said, “Our fourth-quarter and full-year results demonstrate the progress we are making in transforming the healthcare experience with our unique collection of businesses. From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America.”
